Sai Life Sciences Peer Comparison
NSE: SAILIFE
₹1,522.20
₹-36.00
(-2.31%)
As on 04-Nov-2026 09:44IST
Market cap
₹33,081 Cr
Revenue (TTM)
₹2,250 Cr
P/E Ratio
91.4
P/B Ratio
13
Div. Yield
0 %
Edit
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
33,081 | 14,779 | 14,279 | 7,897 | 2,366 |
Revenue (₹ Cr) |
2,250 | 4,131 | 3,172 | 979 | 2,901 |
Net Profit (₹ Cr) |
361.74 | 411.10 | 521.27 | 279.70 | 16.16 |
Net Margin (%) |
15.77 | 9.78 | 15.92 | 27.97 | 0.55 |
RoE (%) |
15.47 | 13.13 | 18.10 | 76.43 | 0.29 |
Price to Earnings |
91.45 | 35.95 | 27.63 | 28.23 | 146.40 |
Price-To-Book |
12.96 | 4.40 | 4.49 | 18.60 | 0.36 |
Income Statement (₹ Cr)
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,192.49 | 3,510.50 | 2,950.94 | 878.40 | 2,931.90 |
|
Total Income
|
2,266.90 | 3,582.50 | 3,033.47 | 896.80 | 2,987.84 |
|
Total Expenditure
|
1,584.97 | 2,891.50 | 2,350.16 | 569.40 | 2,366.27 |
|
EBITDA
|
607.53 | 619.00 | 600.78 | 309.00 | 565.63 |
|
Depreciation
|
166.86 | 126.40 | 98.63 | 11.70 | 338.69 |
|
EBIT
|
440.67 | 492.60 | 502.15 | 297.30 | 226.94 |
|
Interest
|
40.88 | 19.30 | 24.13 | 2.00 | 174.18 |
|
Other Income
|
74.40 | 72.00 | 82.53 | 18.40 | 55.94 |
|
Exceptional Items
|
-8.00 | -20.30 | -- | 6.60 | -3.80 |
|
Profit before Tax
|
466.19 | 525.00 | 560.56 | 320.30 | 104.90 |
|
Provision for Tax
|
117.28 | 123.90 | 140.49 | 80.20 | 7.45 |
|
Profit after Tax
|
348.91 | 401.10 | 420.06 | 240.10 | 97.45 |
Liabilities (₹ Cr)
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,483.69 | 3,138.70 | 3,023.16 | 384.00 | 6,676.90 |
|
Minority Interest
|
-- | -- | 29.52 | -- | -- |
|
Non-Current Liabilities
|
321.65 | 318.60 | 268.17 | 229.90 | 2,846.00 |
|
Current Liabilities
|
904.59 | 1,086.20 | 527.09 | 128.40 | 2,317.05 |
|
Total Liabilities
|
3,709.93 | 4,620.30 | 3,855.82 | 750.80 | 11,911.40 |
Assets (₹ Cr)
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,228.49 | 1,925.10 | 1,125.20 | 248.00 | 8,997.85 |
|
Current Assets
|
1,481.44 | 2,618.40 | 2,722.74 | 494.30 | 2,842.10 |
|
Total Assets
|
3,709.93 | 4,620.30 | 3,855.82 | 750.80 | 11,911.40 |
|
Total Debt*
|
95.13 | 0.00 | 29.59 | 0.00 | 2,775.40 |
|
Net Current Assets
|
576.85 | 1,532.20 | 2,195.65 | 365.90 | 525.05 |
|
Contingent Liabilities
|
97.31 | -- | -- | 1.50 | 428.74 |
Cashflow (₹ Cr)
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
509.13 | 650.80 | 458.13 | 174.80 | 491.45 |
|
Cash Flow from Investing Activities
|
-395.41 | -512.40 | -248.27 | 7.60 | -245.34 |
|
Cash from Financing Activities
|
-123.68 | -82.60 | -70.93 | -134.50 | 200.58 |
|
Net Cash Inflow / Outflow
|
-9.96 | 55.80 | 138.93 | 47.90 | 446.69 |
Ratios
Profitability Ratios
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
ROCE (%)
|
20.97 | 18.92 | 21.10 | 98.11 | 3.21 |
|
ROE (%)
|
15.16 | 14.14 | 15.31 | 73.20 | 1.56 |
|
ROA (%)
|
10.09 | 10.31 | 11.85 | 37.26 | 0.89 |
|
EBIT Margin (%)
|
31.10 | 19.68 | 23.16 | 37.27 | 21.20 |
|
Net Margin (%)
|
15.39 | 11.20 | 13.85 | 26.77 | 3.26 |
|
Cash Profit Margin (%)
|
23.50 | 15.03 | 17.07 | 27.35 | 14.88 |
Growth Ratios
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
29.38 | 23.64 | 12.51 | 21.24 | 8.13 |
|
EBIT Growth (%)
|
53.37 | 7.72 | 14.07 | 15.44 | 26.69 |
|
Net Profit Growth (%)
|
105.08 | -1.38 | 9.79 | 32.65 | 2,907.72 |
|
EPS Growth (%)
|
101.82 | -1.79 | 9.81 | 32.65 | 2,908.18 |
|
Book Value Growth (%)
|
16.76 | 19.89 | 22.41 | 41.18 | 14.50 |
Valuation Ratios
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Price / Earnings
|
58.91 | 26.06 | 17.04 | 43.36 | 20.92 |
|
Price / Book Value
|
8.29 | 3.38 | 2.36 | 27.11 | 0.31 |
|
Dividend Yield (%)
|
0.00 | 0.52 | 0.57 | 1.66 | 0.00 |
|
EV/EBITDA
|
30.12 | 14.57 | 9.02 | 30.65 | 6.15 |
|
Market Cap (₹ Cr)
|
20,554.39 | 10,450.76 | 7,121.50 | 10,410.62 | 2,038.26 |
Solvency Ratios
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.04 | 0.00 | 0.01 | 0.00 | 0.42 |
|
Short term debt to equity ratio
|
0.03 | -- | 0.01 | -- | 0.13 |
|
Current Ratio
|
1.64 | 2.41 | 5.17 | 3.85 | 1.23 |
|
Quick Ratio
|
1.47 | 2.41 | 3.32 | 3.37 | 0.79 |
|
Interest Coverage
|
12.40 | 28.20 | 24.24 | 161.15 | 1.60 |
Operating Efficiency Ratios
| Sai Life Sciences | Indegene | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.04 | 27.97 | 21.84 | 3.37 | 22.95 |
|
Asset Turnover
|
0.63 | 0.90 | 0.86 | 1.43 | 0.27 |
|
Receivable days
|
60.56 | 90.10 | 71.16 | 8.58 | 83.29 |
|
Inventory Days
|
22.43 | 0.00 | 109.20 | 20.38 | 119.47 |
|
Payable days
|
194.31 | -- | 91.82 | 118.89 | 197.26 |
|
Cash Conversion Cycle
|
-111.32 | -- | 88.55 | -89.93 | 5.50 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
